Genmab — Juli 2018
-
...men er det her ikke t-celle terapi....
-
Om immatics xpresident program her https://immatics.com/x-president.html
-
Bulder - kender du noget til konceptet.
-
Har du nogen fornemmelse af indikationer, eller er det for tidligt.
-
Spændende. Tusind tak
-
About 65% of Genmab's preclinical programs—both in-house and partnered—are based on its Duobody
bsAb technology. “I believe this is going to be the single biggest driver of future income in the antibody space,” said Genmab CEO Jan van de Winkel, Ph.D., in a comment to the journal Nature.https://www.genengnews.com/gen-exclusives/bispecific-antibodies-reemerge/77900838...og nu har GM værktøjet til, at identificere nye target peptider. -
-
Nogen der ved hvornår der er tal for Q2
-
-
Smadsen@ 17. Juli. https://m.nasdaq.com/earnings/report/jnj
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind